News & Insights

Inherited bleeding disorders (iBDs), such as haemophilia A and B, von Willebrand disease (VWD), and Glanzmann thrombasthenia, present unique challenges for health technology assessment (HTA). Treatments are often lifelong, costly, and evolving rapidly, especially with the advent of gene therapies and non-factor replacement options like emicizumab. Economic evaluations (EEs) are essential to guide reimbursement and policy decisions, and modelling plays a central role in these